APPLICATION
ANDA218115
TYPE
ANDA
ORIGINAL APPROVAL
2025-04-02
LATEST ACTION
2025-10-15
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
LIRAGLUTIDEPrescription
LIRAGLUTIDE 18MG/3ML (6MG/ML) · SOLUTION · SUBCUTANEOUS
Approval history
2025-10-15Labeling · Supplement 3 · standardAP
2025-04-02UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.